MENU

ADAP Stock Adaptimmune Therapeutics (ADAP, $1.01) Moving Average Convergence Divergence (MACD) Histogram turned negative on June 4, 2024

A.I.dvisor
at Tickeron.com
06/05/24
Loading...
ADAP - Adaptimmune Therapeutics plc
MACD signal
Bearish Trend
Odds of DOWN Trend
Tickeron
MACD signal
Price: $1.01
Daily change: -$0.06 (-5.61%)
Daily volume: 4M
Capitalization: $258.1M
Industry: Biotechnology
This is a Bearish indicator signaling ADAP's price could decline from here. Traders may explore shorting the stock or put options. A.I. dvisor identified 43 similar cases where ADAP's MACD histogram became negative, and of them led to successful outcomes. Odds of Success:

ADAP in -25.51% downward trend, declining for three consecutive days on November 14, 2024

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ADAP declined for three days, in of 330 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 46 cases where ADAP's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Momentum Indicator moved below the 0 level on November 14, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ADAP as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ADAP turned negative on November 14, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

The Aroon Indicator for ADAP entered a downward trend on November 08, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ADAP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAP advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.571) is normal, around the industry mean (14.655). P/E Ratio (0.000) is within average values for comparable stocks, (96.848). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.824). ADAP has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (1.004) is also within normal values, averaging (218.428).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. ADAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

View a ticker or compare two or three
ADAP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of vaccines and cancer immunotherapy products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com